Citadel Advisors’s Tourmaline Bio TRML Stock Holding History

Citadel Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,400	Closed	-$258K	–	14092
2025 Q3	$258K	Buy	+5,400	New	+$150K	﹤0.01%	10688
2025 Q2	–	Sell	-2,200	Closed	-$33.5K	–	15129
2025 Q1	$33.5K	Sell	2,200 -2,100	-49%	-$33.7K	﹤0.01%	12710
2024 Q4	$87.2K	Sell	4,300 -5,500	-56%	-$138K	﹤0.01%	11670
2024 Q3	$252K	Sell	9,800 -6,500	-40%	-$108K	﹤0.01%	9658
2024 Q2	$210K	Buy	16,300 +7,500	+85%	+$121K	﹤0.01%	9826
2024 Q1	$202K	Buy	+8,800	New	+$310K	﹤0.01%	10296

Citadel Advisors's TRML Position: Q4 2025 in Review

Citadel Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 95,621 shares — an estimated $4.57M sold.

Citadel Advisors first reported a position in TRML in Q2 2021 and held it in 16 quarters. The position peaked at $40.7M in Q4 2021. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Citadel Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 95,621 Tourmaline Bio shares in Q4 2025, an estimated $4.57M.
Citadel Advisors first reported a position in Tourmaline Bio in Q2 2021 and held it in 16 quarters.
Citadel Advisors's Tourmaline Bio position peaked at $40.7M in Q4 2021.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.